Tretinoin 0.05% lotion (ALTRENO Lotion) provides a statistically significant improvement in patients with moderate-to-severe acne, compared to placebo. The study was published in the October issue of the Journal of Drugs in Dermatology.

Researchers evaluated the efficacy, safety, and tolerability of a novel tretinoin 0.05% lotion in 1,640 patients with moderate-to-severe acne aged 9 to 58 years. Patients were randomized to receive either tretinoin 0.05% lotion or vehicle.

Tretinoin lotion

The researchers found that tretinoin 0.05% lotion demonstrated statistically significant superiority to the vehicle in reducing inflammatory and non-inflammatory lesion counts (both P < 0.001) at week 12, as well as improving acne severity (P < 0.001).


Treatment success (a two-grade improvement in Evaluator Global Severity Scores and "clear" or "almost clear") was reported in 18% of patients.  For patient satisfaction (P < 0.001) and acne-specific quality-of-life domains, tretinoin 0.05% lotion also showed significantly greater benefits compared to vehicle.

There were no substantive differences in tolerability between the groups. No patients discontinued treatment because of adverse events. They believe these new data further demonstrate the value that ALTRENO Lotion provides patients with acne vulgaris, and we look forward to bringing the product to market by the end of the month.

Several authors report financial ties to the pharmaceutical industry, including Ortho Dermatologics, which manufactures tretinoin. The study was sponsored by Dow Pharmaceutical Sciences.